Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: In vitro and in vivo studies

Cancer Research

Volumn 69, Issue 23, 2009, Pages 8987-8995

  Cao, Yu ^a   Marks, James D ^b   Marks, John W ^a   Cheung, Lawrence H ^a   Kim, Sehoon ^a,c   Rosenblum, Michael G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; FURIN; GELONIN; IMMUNOTOXIN; RECOMBINANT PROTEIN;

ARTICLE; AUTOPHAGY; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CELL DEATH; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; ONCOGENE NEU; OVARY TUMOR; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AUTOPHAGY; CELL LINE, TUMOR; FEMALE; FURIN; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTOXINS; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGOPEPTIDES; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; RIBOSOME INACTIVATING PROTEINS, TYPE 1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 71549169552     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2693     Document Type: Article

References (48)

1. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1139 (Pubitemid 16169997)
2. Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986;319:230-234 (Pubitemid 16128786)
3. Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986;45:649-657
4. Kapitanovic S, Radosevic S, Kapitanovic M, et al. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997;112:1103-1113 (Pubitemid 27157520)
5. Press MF, Pike MC, Hung G, et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 1994;54:5675-5682 (Pubitemid 24346266)
6. Verri E, Guglielmini P, Puntoni M, et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology 2005;68:154-161 (Pubitemid 41158970)
7. Moulder SL, Arteaga CL. A phase I/II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpresses HER2/neu (ErbB-2). Clin Breast Cancer 2003;4:142-145
8. Kubo M, Morisaki T, Kuroki H, et al. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer. Anticancer Res 2003;23:4443-4449 (Pubitemid 37474897)
9. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-9290
10. Cho HM, Rosenblatt JD, Kang YS, et al. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein. Mol Cancer Ther 2005;4:956-967
11. Wang L, Liu B, Schmidt M, Lu Y, Wels W, Fan Z. Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells. Prostate 2001;47:21-28 (Pubitemid 32246749)
12. Shinohara H, Morita S, Kawai M, et al. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin. J Surg Res 2002;102:169-177 (Pubitemid 34969464)
13. Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res 2007;13:3058-3067 (Pubitemid 46849583)
14. Baluna R, Coleman E, Jones C, Ghetie V, Vitetta ES. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage. Exp Cell Res 2000;258:417-424 (Pubitemid 30483520)
15. Vitetta ES. Immunotoxins and vascular leak syndrome. Cancer J 2000;6 Suppl 3:S218-224.
16. Huhn M, Sasse S, Tur MK, et al. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 2001;61:8737-8742 (Pubitemid 34013885)
17. Rosenblum MG, Shawver LK, Marks JW, Brink J, Cheung L, Langton-Webster B. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models. Clin Cancer Res 1999;5:865-874 (Pubitemid 29180839)
18. Rosenblum MG, Kohr WA, Beattie KL, et al. Amino acid sequence analysis, gene construction, cloning, and expression of gelonin, a toxin derived from Gelonium multiflorum. J Interferon Cytokine Res 1995;15:547-555
19. Li Z, Qu Y, Li H, Yuan J. Truncations of gelonin lead to a reduction in its cytotoxicity. Toxicology 2007;231: 129-136 (Pubitemid 46283156)
20. Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 2002;13: 603-608 (Pubitemid 35448063)
21. Jain M, Chauhan SC, Singh AP, Venkatraman G, Colcher D, Batra SK. Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors. Cancer Res 2005;65:7840-7846 (Pubitemid 41297260)
22. Schier R, Marks JD, Wolf EJ, et al. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1995;1:73-81.
23. McCall AM, Adams GP, Amoroso AR, et al. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol 1999;36:433-445
24. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8:1172-1181 (Pubitemid 35177372)
25. Robinson MK, Shaller C, Garmestani K, et al. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the α-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res 2008;14:875-882 (Pubitemid 351231172)
26. Rosenblum MG, Cheung LH, Liu Y, Marks JW III. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res 2003;63:3995-4002. (Pubitemid 36917918)
27. Hashizume T, Fukuda T, Nagaoka T, et al. Cell type dependent endocytic internalization of ErbB2 with an artificial peptide ligand that binds to ErbB2. Cell Biol Int 2008;32:814-826
28. Hale ML. Microtiter-based assay for evaluating the biological activity of ribosome-inactivating proteins. Pharmacol Toxicol 2001;88:255-260
29. Izidoro MA, Gouvea IE, Santos JA, et al. Study on human furin specificity besides the canonical motif R-X-K/R-R using synthetic peptides derived from its natural substrates, and effects of potassium ions. Arch Biochem Biophys 2009.
30. Kibirev VK, Osadchuk TV, Radavskii I. [Furin and its biological role]. Ukr Biokhim Zh 2007;79:5-18.
31. Zhang L, Zhao J, Wang T, et al. HER2-targeting recombinant protein with truncated Pseudomonas exotoxin A translocation domain efficiently kills breast cancer cells. Cancer Biol Ther 2008;7:1226-1231
32. Clemente R, de la Torre JC. Cell-to-cell spread of Borna disease virus proceeds in the absence of the virus primary receptor and furin-mediated processing of the virus surface glycoprotein. J Virol 2007;81: 5968-5977 (Pubitemid 46847033)
33. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-195 (Pubitemid 34773774)
34. Fortunato F, Burgers H, Bergmann F, et al. Impaired autolysosome formation correlates with Lamp-2 depletion: role of apoptosis, autophagy, and necrosis in pancreatitis. Gastroenterology 2009;137:350-60, 360.
35. Thorburn J, Horita H, Redzic J, Hansen K, Frankel AE, Thorburn A. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ 2009;16:175-183
36. Deckert PM. Current constructs and targets in clinical development for antibody-based cancer therapy. Curr Drug Targets 2009;10:158-175
37. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008;14:154-169
38. Chen SY, Zani C, Khouri Y, Marasco WA. Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Ther 1995;2:116-123
39. Oda Y, Tsuneyoshi M. Recent advances in the molecular pathology of soft tissue sarcoma: implications for diagnosis, patient prognosis, and molecular target therapy in the future. Cancer Sci 2008;100:200-208
40. Pai-Scherf LH, Villa J, Pearson D, et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res 1999;5:2311-2315 (Pubitemid 29437307)
41. von MG, Harder S, Hovelmann S, et al. Phase I clinical study of the recombinant antibody toxin scFv (FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res 2005;7:R617-626.
42. Goyal A, Batra JK. Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins. Biochem J 2000;345 Pt 2:247-254 (Pubitemid 30077164)
43. Wang T, Zhao J, Ren JL, et al. Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells. Cancer Res 2007; 67:11830-11839
44. Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 2004;16: 663-669 (Pubitemid 39463117)
45. Kepp O, Tesniere A, Schlemmer F, et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009;14:364-375
46. Veenendaal LM, Jin H, Ran S, et al. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A 2002;99:7866-7871
47. Lyu MA, Cheung LH, Hittelman WN. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA. Mol Cancer Ther 2007;6:460-470
48. Kamb A. What's wrong with our cancer models? Nat Rev Drug Discov 2005;4:161-165